Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology C O R P O R AT E P R E S E N TAT I O N AU G U S T 2 0 2 6
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: VISION 2030 is our Engine for Long-term Growth
VISION 2030 is our Engine for Long-term Growth 50k patients on 10labeled 5 late-stage treatment indications molecules Build diversified Scale VYVGART Expand across immunology portfolio in in MG and CIDP indications and assets FcRn and beyond 3
Slide 4: 2026 Strategic Priorities
2026 Strategic Priorities Impact More Patients Shape Long-Term Deliver Next Wave with VYVGART Future of FcRn of Innovation Deliver broadest MG label First empa Phase 3 readout Advance combination (MMN) approaches AIM and ITP Phase 3 readouts 4 Phase 3 molecules 3 Clinical-stage FcRn Expand into rheu
Slide 5: Impact More Patients with VYVGART & Shape Long-Term Future with FcRn
Impact More Patients with VYVGART & Shape Long-Term Future with FcRn 5
Slide 6: VYVGART Growth Momentum Continues Across MG and CIDP
VYVGART Growth Momentum Continues Across MG and CIDP Increasing Breadth & Seronegative gMG Label PFS Driving Demand Depth of Prescription Expansion ~80% of PFS patients >5,000 neurologists First and only new to VYVGART biologic approved across in 2Q/26 Earlier-line use all gMG serotypes Internal arg
Slide 7: VYVGART Has the Broadest Label Across all gMG
VYVGART Has the Broadest Label Across all gMG Now Approved VYVGART is the First and Only Targeted Treatment Approved for Adults with gMG across all Serotypes Anti-AChR antibody positive Anti-MuSK antibody positive Anti-LRP4 antibody positive Triple seronegative Mary Beth, MG Patient 7
Slide 8: Strong Early Momentum Following gMG Label Expansion
Strong Early Momentum Following gMG Label Expansion PATIENTS PHYSICIANS PAYERS +11k >80% ~55% Patients now Of seronegative MG U.S. commercial eligible in U.S. treaters covered lives covered “I honestly sat at my Significant Halo effect on Most plans remove unmet need gMG patients serology testing co
Slide 9: Path to 60K Addressable Patients
Path to 60K Addressable Patients U.S. Addressable MG Patients +25K +7K Growth in Biologics +11K Share of Market 60K Ocular 17K Seronegative Approved for all Submission PFS driving gMG serotypes1 on track expansion Addressable Total Addressable Market at Launch Market in 2030 Source: argenx market re
Slide 10: Evidence Generation Supports CIDP Market Expansion
Evidence Generation Supports CIDP Market Expansion CIDP Market CIDP Evidence Generation Expansion Opportunity +18K Diagnosed, Not Treated Improved grip strength 1 42K +12K For up to 96 weeks Total Diagnosed Patients Successful IVIG switch study 2 Diagnosed, ‘Well-Managed’ on Treatment 87.5% response
Slide 11: Building Our Presence in Rheumatology
Building Our Presence in Rheumatology ALKIVIA Phase 3: UNITY Phase 3: Autoimmune Myositis (AIM) Sjögren’s Disease (SjD) Redefining Biology MSAs1 linked to disease severity IMNM in IMNM; skin rash and treatment Anti-Ro/SSA and Anti-La/SSB response in DM are hallmarks of disease 20K 230K Redefining Tr
Slide 12: Autoimmune Myositis is a Quintessential argenx Opportunity
Autoimmune Myositis is a Quintessential argenx Opportunity IMNM 20K Zero approved or Clear Biology late-development therapies Breakthrough Therapy Designation for IMNM High Unmet Need A Multi-blockbuster Opportunity DM 40K Heterogeneous disease; Limited treatments U.S. Prevalence 12
Slide 13: Significant and Sustained Response Through Weeks
Significant and Sustained Response Through 52 Weeks Mean TIS Improvement in IMNM + DM Consistent Treatment Effect Through Week 52 Least Square Mean (±SE) Total Improvement Score Consistent across core TIS measures with benefit in both muscle and skin domains Consistent across primary and secondary e
Slide 14: Consistent Response Across IMNM and DM
Consistent Response Across IMNM and DM Baseline Characteristics Mean TIS Evaluated at 52 Weeks Efgartigimod Placebo Baseline Characteristics IMNM DM IMNM DM IMNM + DM Combined Population (n=46) (n=26) (n=46) (n=28) Active Placebo Delta p-value Age (mean, years) 55.5 51.3 54.1 51.3 47.95 32.56 15.39
Slide 15: Building a Sustainable FcRn Franchise
Building a Sustainable FcRn Franchise Today Tomorrow Differentiated Efficacy and Patient Experience Enduring FcRn Leadership ARGX-213 ARGX-124 ARGX-XXX Phase 3 ready Phase 1 Future molecules FcRn Optimizing patient PFS Autoinjector Small volume Oral experience approved Est 2027 delivery peptides Exp
Slide 16: Deliver Next Wave of Innovation
Deliver Next Wave of Innovation 16
Slide 17: Transformative Potential Across Pipeline Programs
Transformative Potential Across Pipeline Programs Efgartigimod Empasiprubart Adimanebart ARGX-213 ARGX-121 First-in-class Potent C2 MuSK agonist FcRn: Sustained IgA Sweeping Fc Fragment antibody antibody IgG reduction Antibody 15+ 3+ 2+ 15+ 3+ Indications Indications Indications Indications Indicati
Slide 18: Attractive De-Risked Profile of Phase 3 Studies
Attractive De-Risked Profile of Phase 3 Studies Autoimmune Ocular MG MMN ITP Sjogren’s Myositis ADAPT ocular ALKIVIA EMPASSION ADVANCE Phase 3 IV domain data Phase 3 across multiple Proof of Concept RHO and DAHLIAS Real world data Japan Proof of concept AIM subtypes Real-world case reports Cumulativ
Slide 19: A Pivotal Year for Empasiprubart
A Pivotal Year for Empasiprubart Sustained Grip Strength Improvement in Phase 2 ARDA OLE ARDA+ Open Label 12K patients across MMN ARDA Phase 2 key markets Grip strength change from baseline (kPA) UNMET NEED 40% Initially 0 Targeted 60% Progression misdiagnosed treatments despite treatment DISEASE BU
Slide 20: Successfully Advancing Next Wave of Molecules
Successfully Advancing Next Wave of Molecules ARGX-213: Convenient Monthly Dose Achieved ARGX-121: Human Data Show Rapid and Total in Humans IgA Depletion IgG Change from baseline (%) IgA Change from baseline (%) IgA-targeting Fc-ABDEGTM Fab α-albumin Fc-ABDEGTM VHH 20
Slide 21: We pursue the best science - wherever it originates
Licensing Academic Deals Collaborators IIP Biopharma We pursue Acquisitions Partners the best science Innovation Engine - wherever it originates. Efgartigimod Empasiprubart FB102 ARGX-213 TSP-101 Adimanebart ARGX-124 ARGX-121 ARGX-125 ARGX-118 21
Slide 22: Forte Biosciences is a Strong Strategic Fit for argenx
Forte Biosciences is a Strong Strategic Fit for argenx Why Forte Why argenx Novel Biology Complementary to argenx FB102 is a first-in-class anti-CD122 antibody immunology portfolio Clinically Validated Proven pipeline-in-a-product Phase 1b POC data in vitiligo, celiac disease development and product
Slide 23: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline IIP/Preclinical Phase 1 PoC Registrational Approved ARGX-118 (Galectin) AMR Ocular MG gMG1 – CIDP – ITP (Japan) ARGX-124 (FcRn) Scleroderma ITP 25 ARGX-125 AIE Graves’ Disease Active IIP TSP-101 (Fn14) DGF* Sjogren’s Disease programs PROGRAMS SMA Auto
Slide 24: 5 Readouts Over Next 15 Months
5 Readouts Over Next 15 Months Phase 3 Data Readouts EFGARTIGIMOD EMPASIPRUBART ITP 1H 2027 MMN 4Q 2026 Sjogren’s Disease 2H 2027 CIDP (2 studies) 2H 2027 24
Slide 25: 2Q26 Financials
2Q26 Financials argenx 25
Slide 26: Product Net Sales of $1.5 Billion in Q2
Product Net Sales of $1.5 Billion in Q2 Product Net Sales by Quarter 1.516 Quarter over Quarter (QoQ) growth: 2Q26 vs 1Q26 $’m (in millions of $) Q2 2026 Q1 2026 Growth Growth % * China 1.286 1.298 US 1,273 1,107 166 15% RoW Japan 1) 102 67 35 55% Japan 1.127 Rest of the World 136 112 24 22% US 949
Slide 27: Q2 2026 Financial Summary
Q2 2026 Financial Summary Operating profit of $0.5B +146% YoY $3.6 billion in cash and cash equivalents and $1.6 billion in current financial assets Ended Q2 with cash† of $5.2B † Alternative Performance Measure (APM). Refer to the APM Statement. *Comparative figures have been aligned with the prese
Slide 28: Innovation Has No Value Unless it Provides Meaningful Benefit to Patients
Innovation Has No Value Unless it Provides Meaningful Benefit to Patients 28
Slide 29: Alternative Performance Measure Statement
Alternative Performance Measure Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for th